Related Experiment Videos
Potential new drug targets for osteoporosis
1Orthopedic and Rheumatology Institute, Cleveland Clinic, Cleveland, OH 44195, USA. dealc@ccf.org [corrected]
Nature Clinical Practice. Rheumatology
|December 23, 2008
Summary
Osteoporosis treatments are antiresorptive or anabolic. New antiresorptive drugs like denosumab and odanacatib target osteoclast activity, while novel anabolic agents aim to stimulate new bone formation for better osteoporosis management.
Area of Science:
- Bone biology and pharmacology
- Endocrinology and metabolic diseases
Background:
- Osteoporosis is a global health issue characterized by reduced bone density and increased fracture risk.
- Current treatments include antiresorptive agents (bisphosphonates, SERMs, calcitonin, estrogen) and anabolic agents (teriparatide).
Purpose of the Study:
- To review existing and emerging therapeutic agents for osteoporosis.
- To highlight novel antiresorptive and anabolic treatments in development.
Main Methods:
- Review of current literature on osteoporosis treatments.
- Discussion of novel drug targets and mechanisms of action.
Main Results:
- Novel antiresorptive agents include denosumab (anti-RANKL) and odanacatib (cathepsin K inhibitor).
- Emerging anabolic agents target Wnt signaling (sclerostin/dickkopf-1 antibodies), calcium-sensing receptors, and activin pathways.
Conclusions:
- Ongoing research is expanding therapeutic options for osteoporosis.
- New agents offer targeted approaches to inhibit bone resorption and stimulate bone formation.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...